STOCK TITAN

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024, at 1:30 p.m. ET. The company's management team will also have one-on-one meetings during the conference. The live webcast and archived recording of the event can be accessed on the Phathom website. Recordings will be available for 90 days after the meeting.
Positive
  • None.
Negative
  • None.

FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 1:30 p.m. ET.

Company management will also participate in one-on-one meetings during the conference, which will run from February 7-8, 2024.

To access the live webcast and an archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the U.S., Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.


Phathom Pharmaceuticals will participate in the conference on February 7, 2024, at 1:30 p.m. ET.

The live webcast and archived recording can be accessed on the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

Recordings will be available for 90 days following the conclusion of the meeting.
Phathom Pharmaceuticals Inc

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.